Cochrane for Clinicians
Putting Evidence into Practice
Effects of Altered Dietary Salt Intake in Patients with Chronic Kidney Disease
Am Fam Physician. 2017 Apr 1;95(7):423-424.
Author disclosure: No relevant financial affiliations.
In patients with chronic kidney disease (CKD), does altering dietary salt intake affect risk factors or delay cardiovascular or renal complications?
Reducing salt intake lowers blood pressure and reduces proteinuria in patients with CKD, but there is no evidence to determine whether lowering salt consumption leads to clinically significant reductions in end-stage renal disease, cardiovascular events, or all-cause mortality.1 (Strength of Recommendation: C, based on a review of limited, though consistent, high-quality disease-oriented studies.)
CKD is a progressive condition often encountered by family physicians; it is both a complication of commonly encountered disease (e.g., hypertension, diabetes mellitus)2 and an independent risk factor for cardiovascular disease.3 Patients with end-stage renal disease incur dramatically higher costs of care4 and have markedly increased mortality.5 Reliable interventions that may delay or prevent progression of CKD have not been fully elucidated. Restriction of dietary sodium (salt) intake is often recommended in these patients. This review sought
REFERENCESshow all references
1. McMahon EJ, Campbell KL, Bauer JD, Mudge DW. Altered dietary salt intake for people with chronic kidney disease. Cochrane Database Syst Rev. 2015;(2):CD010070....
2. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–2047.
3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [published correction appears in N Engl J Med. 2008;18(4):4]. N Engl J Med. 2004;351(13):1296–1305.
4. Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl. 2003;(87):S24–S31.
5. Hunsicker LG. The consequences and costs of chronic kidney disease before ESRD. J Am Soc Nephrol. 2004;15(5):1363–1364.
6. Kotchen TA, Cowley AW Jr, Frohlich ED. Salt in health and disease—a delicate balance. N Engl J Med. 2013;368(13):1229–1237.
7. NKF K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. http://www2.kidney.org/professionals/KDOQI/guidelines_bp/guide_6.htm. Accessed July 12, 2016.
8. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012;2(5):337–414.
These are summaries of reviews from the Cochrane Library.
This series is coordinated by Corey D. Fogleman, MD, Assistant Medical Editor.
A collection of Cochrane for Clinicians published in AFP is available at http://www.aafp.org/afp/cochrane.
Copyright © 2017 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions